These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17932968)

  • 61. The IBD SGI Diagnostic Test Is Frequently Used by Non-gastroenterologists to Screen for Inflammatory Bowel Disease.
    Berinstein JA; Waljee AK; Stidham RW; Higgins PDR; Govani SM
    Inflamm Bowel Dis; 2018 Apr; 24(5):e18. PubMed ID: 29688480
    [No Abstract]   [Full Text] [Related]  

  • 62. Serologic tests are not helpful in managing inflammatory bowel disease.
    Present DH
    Inflamm Bowel Dis; 2002 May; 8(3):227-9; discussion 223, 230-1. PubMed ID: 11979147
    [No Abstract]   [Full Text] [Related]  

  • 63. Is urotensin II a new inflammatory marker of inflammatory bowel disease?
    Vernero M
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):173-174. PubMed ID: 31347342
    [No Abstract]   [Full Text] [Related]  

  • 64. Re: hepatocyte growth factor and inflammatory bowel disease.
    Couper RL
    J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):231; author reply 231-2. PubMed ID: 12187305
    [No Abstract]   [Full Text] [Related]  

  • 65. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Vradelis S; Kouklakis G
    Scand J Gastroenterol; 2014 Nov; 49(11):1397. PubMed ID: 25228025
    [No Abstract]   [Full Text] [Related]  

  • 66. [Understanding the diagnostic approaches and the disease monitoring of IBD from the clinical practice guideline 2020 -including biomarkers].
    Shinzaki S; Iijima H; Takehara T
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(7):598-606. PubMed ID: 34248072
    [No Abstract]   [Full Text] [Related]  

  • 67. New genetic and clinical features of neonatal inflammatory skin and bowel disease 1.
    Capon F
    Br J Dermatol; 2022 Jun; 186(6):920. PubMed ID: 35522163
    [No Abstract]   [Full Text] [Related]  

  • 68. Serologic Markers in the Diagnosis and Management of IBD.
    Vermeire S
    Gastroenterol Hepatol (N Y); 2007 Jun; 3(6):424-6. PubMed ID: 23329899
    [No Abstract]   [Full Text] [Related]  

  • 69. Emerging Strategies in the Use of IBD-related Serologic Markers.
    Dubinsky MC
    Gastroenterol Hepatol (N Y); 2008 Aug; 4(8):557-9. PubMed ID: 21960935
    [No Abstract]   [Full Text] [Related]  

  • 70. The Role of Serologic and Genetic Testing in IBD: Now and Looking Ahead.
    McGovern D
    Gastroenterol Hepatol (N Y); 2010 Sep; 6(9):550-2. PubMed ID: 21088742
    [No Abstract]   [Full Text] [Related]  

  • 71. Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype.
    Wang ZZ; Shi K; Peng J
    Biomed Rep; 2017 Apr; 6(4):401-410. PubMed ID: 28413638
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of aggressive inflammatory bowel disease.
    Yarur AJ; Strobel SG; Deshpande AR; Abreu MT
    Gastroenterol Hepatol (N Y); 2011 Oct; 7(10):652-9. PubMed ID: 22298958
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current and future role of biomarkers in Crohn's disease risk assessment and treatment.
    Tamboli CP; Doman DB; Patel A
    Clin Exp Gastroenterol; 2011; 4():127-40. PubMed ID: 21753895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characterization of changes in serum anti-glycan antibodies in Crohn's disease--a longitudinal analysis.
    Rieder F; Lopez R; Franke A; Wolf A; Schleder S; Dirmeier A; Schirbel A; Rosenstiel P; Dotan N; Schreiber S; Rogler G; Klebl F
    PLoS One; 2011 May; 6(5):e18172. PubMed ID: 21573154
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serum antibodies to Mycobacterium avium subspecies paratuberculosis combined with anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients: prevalence and diagnostic role.
    Biet F; Gendt L; Anton E; Ballot E; Hugot JP; Johanet C
    Dig Dis Sci; 2011 Jun; 56(6):1794-800. PubMed ID: 21221802
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD.
    Devlin SM; Dubinsky MC
    Inflamm Bowel Dis; 2008 Jan; 14(1):125-8; discussion 132-3. PubMed ID: 17932968
    [No Abstract]   [Full Text] [Related]  

  • 78. Serologic and genetic markers do not aid in the determination of the clinical course and severity of patients with inflammatory bowel disease.
    Murphy SJ; Kornbluth A
    Inflamm Bowel Dis; 2008 Jan; 14(1):129-31; discussion 132-3. PubMed ID: 17932969
    [No Abstract]   [Full Text] [Related]  

  • 79. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 80. What is the role of serological markers in the diagnosis of IBD?
    Dubinsky MC
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S185-6. PubMed ID: 18816787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.